The Shkreli Pill

In this episode, Martin sets his sights on achieving 1000% year-to-date gains and outlines the high-risk trades he’s taking to reach that goal. He discusses his short position in Anavex ($AVXL), explaining his reasoning and evidence behind calling out what he views as a “scam trial,” and shares broader thoughts on risk-taking and conviction in biotech trading.

In this episode, Martin explains his strategy for selling CAPR and managing his ongoing Sarepta recovery trade. He also discusses recent developments involving Sam Altman and shares his thoughts on the “Burning Apes” phenomenon, connecting each topic to broader market behavior and investor sentiment.

In this episode, Martin reviews Warren Buffett’s final letter to Berkshire Hathaway shareholders, interpreting its deeper meaning for investors and the broader market. He highlights the key themes in Buffett’s message—discipline, patience, and value—and explains how they apply to today’s investment landscape.

In this episode, Martin discusses reports that Microsoft still hasn’t paid its outstanding bills to Coreweave and what that could mean for both companies. He also analyzes recent earnings from CAPR and CRWV, breaking down their results and assessing how they fit into the current market environment.

In this compilation episode, Martin argues that a shift toward fundamental investing is imminent and demonstrates the reasoning behind his view. Through selected highlights and past analyses, he illustrates how valuation discipline and real earnings power are set to regain dominance in the market.

In this episode, Martin revisits the core principles behind growth stock valuations and argues that many investors have forgotten the logic that once guided them. He applies this framework to Tesla, Palantir, Duolingo, and Google, examining how each company’s fundamentals align—or clash—with their current market pricing.

In this episode, Martin critiques the surge in Palantir (PLTR) call options, calling it a degenerate gamble detached from fundamentals. He evaluates Duolingo’s stock, describing it as a strong but risky play, and provides an update on his ongoing position and outlook for Biohaven.

In this episode, Martin reveals his full trading record, showing how he achieved a 477% gain and the key moves behind his performance. He explains why he’s now all in on Biohaven stock and reviews IONQ’s latest earnings, highlighting what the results mean for the broader tech and biotech markets.

In this episode, Martin breaks down his trading approach to Sarepta and reviews the latest earnings reports from AMD and Super Micro Computer (SMCI). He shares his candid opinions on Michael Burry’s market views and concludes with an in-depth review of Amgen (AMGN) stock.

In this episode, Martin explains why he believes making money in a bear market can be straightforward with the right strategy. He shares his latest forecast for QURE, discusses his ongoing trades in Sarepta, and provides updated thoughts on Palantir’s performance and valuation.

In this episode, Martin examines how a single FDA-related hint caused QURE stock to surge and what it reveals about market sensitivity to biotech news. He also discusses his outlook on SPRB, speculating on when it could reach the $500 mark, and provides analysis of Uniqure and UnitedHealth stocks within the broader healthcare landscape.

In this episode, Martin shares that Sarepta has grown to represent 40% of his portfolio and explains the reasoning behind his conviction. He discusses the recent crash in QURE stock, provides an updated forecast for Biohaven, and analyzes what he views as an emerging bubble in Palantir.

In this episode, Martin analyzes Walmart’s valuation and explains why he believes it signals a broader market shift toward caution and liquidity. He also reviews Reddit’s recent earnings, interpreting them as a warning sign for speculative stocks and overvalued growth plays.

In this episode, Martin examines Berkshire Hathaway’s record $382 billion cash position and what it signals about market sentiment and opportunity. Through a compilation of key investing insights from recent streams, he shares the lessons and “gems” he believes are most relevant for navigating today’s uncertain environment.

In this episode, Martin reveals which meme stock he’s currently long on and explains the reasoning behind the position. He also provides an analysis of Taiwan Semiconductor, discusses recent developments with Tesla and Apple, and ties these insights into his broader market strategy.

In this episode, Martin reflects on growing market uncertainty and the idea that “nothing is safe anymore.” He highlights why he sees Biohaven as having 3x potential, conducts a detailed analysis of Berkshire Hathaway’s stock, and shares updated perspectives on Apple and Meta within the broader market context.

In this episode, Martin evaluates whether Meta has become a clear buying opportunity at its current valuation. He compares Meta’s positioning to Google, Apple, and Nvidia, offering his stock forecasts for each and outlining the key factors driving his outlook on big tech performance.

In this episode, Martin draws parallels between Intel’s historical rise and Nvidia’s current trajectory, highlighting the patterns that concern him as an investor. He provides an in-depth stock analysis of Nvidia, discusses potential risks ahead, and offers updated thoughts on SPRB and its place in his broader market view.

In this episode, Martin discusses his latest options trade on CAPR and how he’s positioning ahead of potential market moves. He reviews new data related to Summit stock and examines Nvidia’s growing involvement in quantum computing, outlining how these developments could shape his upcoming strategies.

In this episode, Martin reacts to new BTQ contract developments that have raised concerns about his position. He discusses the implications of the news for Quantum, explores the role of elliptic curve cryptography in modern finance, and connects these concepts to the broader outlook for Bitcoin.

In this episode, Martin reviews Intellia’s recent performance and explains why the outlook doesn’t appear promising. He discusses his upcoming short thesis on CAPR and provides a detailed analysis of Summit stock, focusing on valuation, catalysts, and potential risks.

In this episode, Martin points to a Korean stock he believes deserves close attention and explains why he’s bullish on RVMD and Nvidia’s AI GPU positioning. He also references insights from Nassim Taleb to frame his broader perspective on market risk and asymmetric opportunity.

In this episode, Martin explores how the definition of an asset has shifted in today’s market environment and what that means for investors navigating inflated valuations. He highlights one key Warren Buffett principle that he believes is essential for surviving speculative bubbles and explains why he personally avoids trading options despite their popularity.

In this episode, Martin analyzes the “Tiger Cub” style of investing, explaining why their trading approach has appeared nearly invincible in certain market cycles. He also challenges the common perception of Palantir, arguing that it functions more like a hedge fund than a traditional tech company.

In this episode, Martin argues that there’s a largely overlooked segment of the market presenting strong value opportunities and urges investors to act quickly. He also discusses his views on shorting Tesla, reflects on Warren Buffett’s investment philosophy in the current environment, and provides an update on Beyond Meat (BYND) stock.